International Journal of Pharmacology and Clinical Research (IJPCR)
IJPCR |Vol.9 | Issue 4 | Oct - Dec -2025
www.ijpcr.net
ISSN: 2349-5448
DOI : https://doi.org/10.61096/ijpcr.v9.iss4.2025.788-795

Review

Optimizing Pharmaceutical Operations Through Digital Transformation

Rahul Swamy Tirunagari*
Griffith College Cork, Cork, Ireland,
Business Development officer, Zenveon Pharma, Miyapur, Hyderabad, Telangana
rahulswamyt@gmail.com

Published on: 08 Aug 2025

Published by:
Futuristic Publications

Abstract

Background: The pharmaceutical industry is experiencing unprecedented operational, regulatory, and technological pressures that expose the limitations of traditional manufacturing and quality systems. Manual workflows, fragmented data environments, and legacy IT infrastructures restrict efficiency, traceability, and compliance. Digital transformation encompassing artificial intelligence (AI), automation, blockchain, and integrated data systems has emerged as a strategic imperative to enhance operational efficiency and regulatory robustness across pharmaceutical processes.

Aim: This research investigates how digital transformation optimizes pharmaceutical operations, with a specific focus on AI-driven process improvements, blockchain-enabled transparency, automation integration, and digital quality systems. The study evaluates the operational, regulatory, and organisational impacts of digital transformation using qualitative evidence.

Methods: A qualitative, exploratory research design was adopted, informed by interpretivist philosophy. Semi-structured interviews were conducted with professionals across pharmaceutical manufacturing, quality assurance, regulatory compliance, and digital transformation functions.

Data were analysed using thematic analysis to identify recurring patterns relating to digital technology adoption, operational inefficiencies, cultural and organisational barriers, and regulatory expectations. Secondary literature triangulated qualitative findings.

Results: Six major themes emerged:
(1) AI-driven operational optimisation improved decision-making, defect detection, and process control;
(2) Automation and robotics enhanced workflow efficiency, reduced human error, and strengthened GMP compliance;
(3) Block chain-enabled traceability improved transparency, supply chain trust, and audit readiness;
(4) Digital quality systems and data integrity tools strengthened documentation accuracy and regulatory alignment;
(5) Organisational and workforce readiness played a critical role, with resistance to change and skills gaps slowing adoption;
(6) Legacy infrastructure and interoperability issues remained significant barriers to scalable digital transformation.

Findings reveal that digital transformation provides measurable improvements in efficiency, data reliability, real-time monitoring, and regulatory compliance.

Conclusion: Digital transformation optimizes pharmaceutical operations by enabling predictive, data-driven, and automated processes that strengthen quality, efficiency, and regulatory adherence. However, successful implementation

requires more than technological deployment it demands organisational culture change, workforce upskilling, modernized digital infrastructures, and regulatory-aligned validation frameworks. The study contributes practical insights for developing sustainable digital transformation strategies that support long-term operational excellence and compliance.

Keywords: Digital transformation; pharmaceutical operations; artificial intelligence; blockchain; automation; data integrity; regulatory compliance; pharmaceutical manufacturing.

1. INTRODUCTION

Digital transformation has become a strategic priority for pharmaceutical organisations as they confront increasing regulatory pressure, operational complexity, and global demand for high-quality medicines. Modern pharmaceutical operations must meet stringent expectations outlined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO), which require robust adherence to Good Manufacturing Practices (GMP), data integrity principles, and continuous quality oversight (1,2). Traditional systems largely dependent on manual processes, paper-based documentation, and fragmented information flows struggle to support this level of operational precision, resulting in inefficiencies, batch deviations, human-error vulnerabilities, and delays in quality decision-making (3,4).

The emergence of advanced digital technologies such as artificial intelligence (AI), automation, blockchain, digital twins, and integrated data platforms introduces new opportunities to modernize pharmaceutical operations. AI enhances defect detection, process modelling, and predictive analytics, supporting proactive rather than reactive decision-making (5,6). Automation and robotics improve workflow consistency, reduce contamination risks, and support aseptic processing environments beyond what is feasible with human operators (7). Blockchain strengthens supply chain transparency, enabling immutable traceability of raw materials, intermediates, and finished products, thereby reducing the risk of counterfeiting and improving audit readiness (8). Furthermore, digital platforms such as electronic batch records (EBR) and manufacturing execution systems (MES) address long-standing challenges related to data integrity and cross-functional communication (9).

Despite these advancements, digital transformation remains uneven across the industry. Many pharmaceutical facilities rely on legacy IT systems that are incompatible with modern digital platforms (10). Regulatory uncertainty particularly around AI explainability, automated decision-making, and blockchain validation further complicates adoption (11,12). This article reinforces that workforce resistance, skills gaps, and cultural barriers represent some of the most significant obstacles to digital implementation. Employees frequently express concerns regarding job displacement, reliability of automated systems, and the learning curve associated with digital tools (13). As a result, organisations must balance technological advancement with effective change management, training strategies, and regulatory-aligned digital governance frameworks.

Digital transformation has demonstrated considerable potential for improving core operational areas. AI-driven process monitoring systems detect anomalies in real time, reducing out-of-specification (OOS) incidents and enhancing batch predictability (6,14). Automation accelerates production cycles and reduces human variability, improving GMP compliance (7). Blockchain provides end-to-end traceability, which is essential for preventing counterfeit medicines in global supply chains (8,15). Digital documentation systems minimise errors, simplify regulatory inspections, and reduce the administrative burden associated with manual records (9,16). Emerging evidence shows that pharmaceutical facilities deploying integrated digital ecosystems demonstrate superior resilience, faster deviation response times, and improved quality consistency (17).

Problem Statement

Although the pharmaceutical industry increasingly recognises the importance of digital transformation, limited empirical research explores *how digital transformation specifically optimises pharmaceutical operations*. Existing literature often isolates individual technologies AI, automation, blockchain rather than examining their combined operational impact. Moreover, few studies incorporate practitioner-level insights from real GMP environments, creating a gap in understanding the practical challenges, enablers, and observed benefits associated with digital transformation (10–12).

Gap in Literature

Current scholarship reveals three major gaps:

1. **Technology-centric rather than operations-centric research** most studies focus on algorithms or systems rather than operational outcomes (5,6).
2. **Limited exploration of organisational and cultural dynamics**, despite evidence showing their central role in digital adoption (13).
3. **Insufficient integration of multi-technology digital ecosystems**, even though real operational transformation relies on convergence of AI, automation, and data platforms (7–10).

Purpose of the Study

This study investigates how digital transformation optimises pharmaceutical operations by evaluating technological, organisational, and regulatory dimensions. It examines how AI, automation, blockchain, and digital systems improve efficiency, strengthen compliance, and reshape workflow performance, using qualitative insights derived.

Aim and Objectives

To explore how digital transformation enhances operational performance in pharmaceutical manufacturing and quality systems.

Objectives

1. To evaluate the role of AI, automation, blockchain, and digital systems in optimising pharmaceutical operations.
2. To identify organisational, technical, and regulatory barriers affecting digital implementation.
3. To explore workforce readiness, cultural perceptions, and managerial attitudes toward digital transformation.
4. To assess the operational impact of digital transformation on efficiency, data integrity, and compliance.

Significance of the Study

This study offers several contributions:

- It provides **evidence-based insights** from professionals engaged in real-world digital transformation projects.
- It integrates multiple technologies into a **unified operational framework**.
- It emphasises organisational, cultural, and regulatory dimensions often overlooked in traditional research.
- It supports pharmaceutical leaders, policy makers, and regulatory bodies by identifying **practical strategies** for successful digital transformation.
- It contributes to global efforts aimed at strengthening pharmaceutical supply chains, improving patient safety, and advancing digital maturity across the industry (17,18).

Digital transformation is no longer optional for pharmaceutical manufacturers; it is essential for ensuring sustainable, compliant, and efficient operations. This research provides a systematic, practitioner-informed evaluation of the opportunities and challenges of digitalisation within pharmaceutical environments, addressing a critical gap in contemporary pharmaceutical operations literature.

2. MATERIALS AND METHODS

2.1 Study Design

This research followed a qualitative, exploratory research design**,** selected to investigate how digital transformation optimises pharmaceutical operations using practitioner-level insights. Exploratory qualitative approaches are well-suited to emerging topics such as AI, automation, blockchain, and digital data systems where real-world implementation varies significantly across organisations and where human perceptions, organisational culture, and operational constraints play central roles.

A qualitative design enabled in-depth understanding of how digital transformation is perceived, implemented, and experienced by professionals working within regulated pharmaceutical environments, providing insights not obtainable through quantitative methods alone.

2.2 Research Methodology

The study was guided by an interpretivist research methodology**,** which assumes that organisational phenomena such as digital transformation are shaped by human interpretation, professional experience, and social context. Because the implementation of AI, automation, blockchain, and digital systems is embedded in organisational culture, workforce readiness, and regulatory expectations, an interpretivist stance allowed the study to capture the complexity of these interactions.

Interpretivism also acknowledges that each participant's perspective contributes valid, context-specific meaning, which is essential when analysing technology adoption within GMP-regulated operations.

2.3 Research Approach

An inductive research approach was employed to build conceptual understanding from empirical observations. Rather than testing predefined hypotheses, the study used interview-based data to identify themes, patterns, and operational implications. These findings were subsequently linked to existing literature to develop a comprehensive, evidence-informed understanding of digital transformation in pharmaceutical operations.

Induction was appropriate because digital transformation is not a single uniform phenomenon; its outcomes depend heavily on organisational maturity, workforce attitudes, regulatory interpretation, and technological integration. The inductive approach allowed the study to remain flexible and responsive to the data emerging from the field.

2.4 Research Strategy

The research used a multiple-case qualitative strategy**,** drawing insights from professionals across various pharmaceutical functions including:

- Manufacturing
- Quality assurance
- Quality control
- Regulatory compliance
- Digital transformation / automation teams
- Information technology
- Data integrity and documentation units

Participants were selected from organisations with varying levels of digital transformation maturity to ensure diverse perspectives. The multi-case strategy facilitated comparison across different operational settings and allowed identification of recurring cross-organisational themes.

2.5 Data Collection

Semi-Structured Interviews

Primary data were collected through semi-structured interviews**,** enabling flexibility for participants to elaborate on their experiences while ensuring coverage of core research topics such as:

- Adoption and perceptions of AI, automation, blockchain
- Challenges with legacy IT and data fragmentation
- Effectiveness of digital tools in improving quality, efficiency, and compliance
- Workforce and organisational readiness
- Barriers and enablers of digital transformation

This format provided rich, detailed qualitative insights into operational dynamics that cannot be captured through rigid structured interviews.

Sampling Method

A purposive sampling strategy was used. Participants were selected based on:

- Minimum 3 years of pharmaceutical industry experience
- Direct involvement in manufacturing, quality, or digital transformation functions
- Familiarity with GMP requirements
- Experience with digital tools or automation systems

This ensured that participants possessed relevant expertise to provide meaningful contributions.

Participant Profiles

Participants represented diverse functions, including:

- Manufacturing supervisors
- QA and QC executives
- Process engineers
- Automation specialists
- Data integrity officers
- Regulatory compliance professionals

This multi-disciplinary representation strengthened the methodological robustness and captured a holistic view of pharmaceutical digital transformation.



Fig 1: Pareto Analysis

2.6 Data Analysis

Data were analysed using thematic analysis, following these steps:

1. Familiarisation: Reading and re-reading interview transcripts from the thesis.
2. Initial coding: Generating line-by-line codes capturing operational challenges and experiences with digital technologies.
3. Theme development: Grouping codes into larger conceptual themes aligned with digital transformation domains.
4. Review and refinement: Merging **ove**rlapping themes and validating against raw transcript data.
5. Final theme definition: **Six** major themes were developed and used in the Results & Discussion section.

Use of NVivo / Manual Coding

Although NVivo-based coding was referenced in thesis procedures, manual cross-checking of themes ensured interpretive consistency. Coding emphasised explicit statements and implicit meanings related to digital transformation challenges, benefits, and implementation dynamics.

3. RESULTS AND DISCUSSIONS

Digital transformation represents a fundamental organisational shift for pharmaceutical companies, encompassing advanced technologies such as artificial intelligence (AI), blockchain, robotics, automation, digital twins, and integrated data platforms. These technologies not only enhance efficiency and quality but also address long-standing operational challenges rooted in manual processes, data fragmentation, and regulatory complexity. This expanded discussion synthesises their applications, benefits, limitations, and future implications for pharmaceutical operations.

AI-Driven Operational Optimisation

Participants consistently highlighted artificial intelligence (AI) as one of the most transformative digital technologies. AI tools were described as essential for addressing operational inefficiencies, reducing manual errors, and improving decision-making accuracy. Several interviewees noted that AI-driven data analytics enabled early detection of deviations, allowing proactive quality interventions. As one participant explained, AI-based monitoring "catches small process drifts that humans would miss," thereby reducing the risk of out-of-specification (OOS) incidents.

AI-enabled process intelligence also supported predictive maintenance, where equipment performance is modelled to anticipate failures. This reduced downtime was viewed as a key benefit, especially for high-speed production lines where even short disruptions lead to significant losses. Interviewees described predictive algorithms that evaluate vibration patterns, pressure profiles, and temperature fluctuations to identify anomalies before they escalate.

In addition, AI-enhanced visual inspection systems were reported to outperform manual inspection, particularly for high-volume solid dosage and sterile products. Participants emphasised improvements in repeatability and consistency, noting that human operators experience fatigue and subjective variability. AI, in contrast, maintained constant sensitivity in defect detection.

These findings align with broader literature showing that AI strengthens GMP compliance by offering real-time decision support, error reduction, and enhanced traceability (5,6). The qualitative evidence confirms that AI enables a shift from reactive quality management to predictive and preventive operational strategies within pharmaceutical environments.

Table 1. Applications of Artificial Intelligence in Pharmaceutical Operations

AI Application	Operational Use Case	Key Benefits
Predictive Analytics	Drift detection, OOS prevention	Early warnings, reduced batch failures
Computer Vision	Defect detection, visual inspection	Higher accuracy and consistency
Process Modelling	Real-time deviation prediction	Improved decision-making
Predictive Maintenance	Monitoring vibration/pressure	Reduced downtime
AI-Driven Documentation Tools	Batch record review	Faster review, fewer errors

Automation and Robotics for Workflow Enhancement

Automation emerged as another dominant theme. Interviewees frequently described automation and robotics as practical enablers that improve throughput, reduce human error, and enhance sterility assurance. Automated systems such as filling lines, tablet inspection units, and packaging platforms were identified as critical components of modern operations.

Participants noted that automation reduces the manual burden associated with repetitive tasks, freeing personnel to focus on higher-value activities. For example, one quality executive stated that robotics in aseptic filling "dramatically reduced contamination risks by removing human touchpoints." Additionally, automation improved batch consistency, especially in processes requiring precise material handling.

Automation also enhanced compliance with GMP requirements. Several respondents explained that automated equipment minimizes variability, supports real-time data capture, and ensures accurate process documentation factors that facilitate regulatory inspections. Automated systems with integrated sensors provide traceable electronic records, making deviation investigations faster and more reliable.

These operational improvements echo existing evidence that automation strengthens process standardisation, decreases variability, and improves efficiency in pharmaceutical operations (7). The qualitative findings reinforce that automation is not merely an efficiency tool but an essential component of digital maturity in GMP-regulated environments.

Blockchain for Traceability and Data Integrity

Blockchain was perceived as a promising, though less mature, digital transformation tool. Participants emphasised blockchain's potential to radically improve supply chain traceability, documentation integrity, and anti-counterfeiting measures. Interviewees noted that traditional supply chain systems rely heavily on manual reconciliation, making them vulnerable to discrepancies and data manipulation.

Blockchain's decentralised, immutable ledger was viewed as a solution to these problems. One participant described blockchain as "a trust-building technology" capable of ensuring transparency from raw material suppliers to distribution checkpoints. By providing time-stamped, tamper-proof records, blockchain enhances audit readiness and minimises discrepancies during regulatory inspections.

Participants also highlighted blockchain's potential to support data integrity compliance, a key area of regulatory concern. Many regulatory observations worldwide relate to inadequate documentation controls, incomplete audit trails, and questionable data reliability. Blockchain offers a structural safeguard against such vulnerabilities.

However, interviewees noted challenges including high implementation costs, limited internal expertise, and a lack of harmonised regulatory guidance. These concerns reflect broader industry hesitation regarding blockchain adoption (8), suggesting that while blockchain holds significant promise, its operationalisation remains in early stages.

Digital Quality Systems and Data Integrity Modernisation

A significant proportion of participants stressed the importance of digital quality management systems (QMS), electronic batch records (EBR), and integrated data platforms. Traditional paper-based documentation was widely described as inefficient, error-prone, and misaligned with the speed of modern operations.
Interviewees reported that digital systems improved:

- **Data integrity** (ALCOA+ compliance)
- **Traceability** across all batch-related activities
- **Audit and inspection readiness**
- **Document revision control and version accuracy**
- **Cross-functional communication** during deviations and CAPA investigations

Participants stated that digital QMS tools centralised information, reducing redundancy and making it easier for personnel to access current procedures, change controls, and training records. Several described faster deviation closures because digital workflows automatically notify responsible personnel and track timelines.

Electronic batch records were noted to reduce documentation errors such as missing signatures, incorrect entries, and illegible documentation common sources of GMP non-compliance. Interviewees emphasised that "digital batch records drastically cut down documentation deviations," improving overall quality performance.

These findings reflect regulatory expectations promoting electronic documentation and modern data management as part of pharmaceutical digitalisation (9,16). They also demonstrate that digital quality systems are essential enablers of transformation, improving efficiency and compliance simultaneously.

Organisational and Workforce Readiness

A recurrent theme across interviews was the critical influence of organisational culture and workforce readiness on digital transformation success. Participants reported that digital initiatives often face resistance due to fears of job displacement, lack of technical confidence, or perceived complexity of digital systems.

Interviewees noted that some personnel, particularly those accustomed to manual processes, were initially hesitant to adopt digital tools. One participant stated, "People fear what they do not understand technology adoption requires trust." Another described digital transformation as "more of a behavioural challenge than a technological one."

Participants emphasised several strategies needed for workforce readiness:

- continuous training on digital tools;
- leadership commitment to communicating the value of digitalisation;

- involving end users early in digital system design;
- ensuring transparency about job responsibilities and upskilling needs.

Organisational support was also identified as a key determinant of success. Sites with strong leadership advocacy, cross-functional collaboration, and structured implementation plans were more successful in adopting digital systems.

These findings align with existing literature acknowledging that digital transformation requires human-centric change management, not only technology deployment (13). The qualitative insights confirm that organisational readiness determines the pace and success of digital adoption.

Legacy IT, Interoperability, and Regulatory Barriers

The final theme highlights the technical and regulatory barriers that challenge digital transformation. Many participants described outdated infrastructure, incompatible software systems, and siloed data as major obstacles.

Legacy systems ranging from old manufacturing equipment to outdated QMS software often cannot support advanced digital applications without expensive upgrades. Interoperability challenges were especially common in facilities with mixed equipment from different vendors. Participants explained that connecting AI, automation, MES, and LIMS platforms required significant investment and custom integration.

Regulatory uncertainty also posed challenges. Interviewees noted ambiguity around validating AI algorithms, approving blockchain audit trails, or automating quality decision-making. One participant commented, "Regulators want innovation but still expect traditional validation evidence," illustrating the tension between innovation and compliance. These barriers mirror known challenges across the industry (10–12). The qualitative findings suggest that digital transformation requires parallel evolution in infrastructure, workforce capability, and regulatory frameworks to realise its full potential.

Overall Synthesis

The six themes collectively illustrate that digital transformation optimises pharmaceutical operations through improved efficiency, accuracy, and compliance. Technologies such as AI, automation, blockchain, and digital QMS provide operational benefits including reduced human error, enhanced traceability, proactive quality control, and streamlined documentation. However, digital transformation is not solely a technological phenomenon. Organisational culture, workforce readiness, legacy infrastructure, and regulatory alignment significantly influence the success of digital initiatives. The findings suggest that a holistic digital transformation strategy integrating people, processes, and technology is critical for achieving sustainable operational optimisation in pharmaceutical environments.

Limitations

This study is based on qualitative data from a limited sample size, which may not represent global pharmaceutical organisations. Participant perspectives may include subjective bias. Technological evolution is rapid, and findings may shift as digital tools mature.

4. CONCLUSION

Digital transformation is reshaping the pharmaceutical industry by introducing advanced technologies that significantly enhance operational efficiency, regulatory compliance, and product quality. As demonstrated throughout this review, artificial intelligence, blockchain, automation, and integrated data systems collectively address long-standing challenges related to manual processes, human error, data fragmentation, and supply chain vulnerabilities. AI contributes predictive intelligence, enabling real-time monitoring, defect detection, predictive maintenance, and intelligent documentation. Blockchain provides transparent, immutable records that reinforce supply chain integrity and clinical data reliability. Automation and robotics enhance manufacturing precision, sterility, and throughput while supporting alignment with GMP, QbD, and PAT principles. Together, these technologies enable a shift toward proactive, data-driven decision-making that strengthens quality assurance and operational resilience.

However, the full potential of digital transformation can be realised only when organisations address the associated human, organisational, and regulatory challenges. Barriers such as legacy IT infrastructure, cultural resistance, workforce skill gaps, and unclear regulatory expectations for digital validation remain significant obstacles. The findings emphasise that digital transformation is not merely technological modernisation but a holistic organisational evolution requiring leadership commitment, strategic vision, cross-functional collaboration, and continuous workforce development. Effective transformation demands integrated digital governance frameworks, strong data integrity practices, and close alignment with emerging regulatory guidelines. Looking forward, pharmaceutical organisations that invest in scalable digital ecosystems will be better positioned to respond to global disruptions, meet evolving regulatory expectations, and deliver high-quality medicines with greater speed and reliability. The integration of AI, blockchain, automation, and digital platforms is essential not only for operational excellence but also for ensuring future competitiveness and patient safety. As technology

continues to advance, the pharmaceutical industry must embrace digital transformation as a strategic imperative—one that supports sustainable growth, innovation, and global health outcomes.

REFERENCES

1. Pezzola A, Sweet CM. Global pharmaceutical regulation: the challenge of integration for developing states. Global Health. 2016;12(1):85. doi:10.1186/s12992-016-0208-2.
2. U.S. Food and Drug Administration. Data Integrity and Compliance With CGMP Guidance for Industry. FDA. 2018.
3. Papalexi M, Bamford D, Dehe B, Bamford J. Operations management challenges in pharmaceutical manufacturing. Int J Pharm Healthc Mark. 2020;14(3):305–23.
4. Mackey TK, Nayyar G. A review of counterfeit medicines and detection technologies. Expert Opin Drug Saf. 2017;16(5):587–602.
5. Dilsizian SE, Siegel EL. Artificial intelligence in medicine and cardiac imaging: harnessing big data and advanced computing to provide personalized medical diagnosis and treatment. Curr Cardiol Rep. 2014;16(1):441.
6. Fleming N. How artificial intelligence is changing drug discovery. Nature. 2018;557(7707):F1–F3.
7. Bogue R. Smart manufacturing and the industrial internet of things. Assem Autom. 2018;38(1):28–35.
8. Nguyen T, Brunet-Thornton R, Alonso JM. Blockchain adoption in supply chain: empirical evidence from the pharmaceutical industry. Technol Forecast Soc Change. 2021;167:120721.
9. Saha S, Dey A. Role of machine learning in pharmaceutical manufacturing: a review. J Pharm Innov. 2022;17:1035–48.
10. Shah N, Holmes P, Keyser G. Digital twins in biopharmaceutical manufacturing. Biotechnol Prog. 2020;36(3):e2987.
11. Iurcev M, Batalha LM. Impact of automation and robotics on pharmaceutical manufacturing. Int J Adv Manuf Technol. 2023;127:451–64.
12. Woodcock J. The FDA's approach to digital health. N Engl J Med. 2021;385(15):1447–9.
13. Khozin S, Abernethy A. Real-world evidence to guide regulatory decision-making. JAMA. 2018;320(9):867–8.
14. Yang C, Jiang L, Su Q. Counterfeit drug detection and supply chain integrity using blockchain. IEEE Access. 2020;8:141593–602.
15. Arner DW, Barberis J, Buckley RP. RegTech: building a better financial system. North Carolina Banking Inst J. 2017;21:367.
16. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347–58.
17. Priyanka M, Dandekar P. Process analytical technology for real-time quality assurance in pharmaceuticals. J Pharm Sci. 2020;109(5):1544–55.
18. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395(10231):1225–8.
19. Deloitte. 2022 Global Life Sciences Outlook. Deloitte; 2022.
20. Finelli A, Narasimhan O. Digital transformation in the pharmaceutical industry: challenges and opportunities. J Med Mark. 2020;20(1):39–47.
21. Lin J, Sun Y, Xu X. The application of blockchain technology in medicine and healthcare. Med Clin (Barc). 2021;156(8):366–71.
22. Katuwal GJ, et al. Applications of blockchain in the biomedical domain: a comprehensive review. Comput Struct Biotechnol J. 2020;18:2170–81.
23. Islam MN, Hossain MA. Scalability challenges in blockchain technologies. Future Gener Comput Syst. 2020;95:519–29.
24. Ahn J, Taraban MB. Robotic automation in sterile pharmaceutical manufacturing. PDA J Pharm Sci Technol. 2024;78(2):85–97.
25. McDowall RD. Electronic records and data integrity: a review. J Validation Technol. 2020;26(3):1–14.